Hua LH - Search Results

1

Comparative effectiveness studies in multiple sclerosis.

Hersh CM, Hua LH. Hersh CM, et al. Among authors: hua lh. Neurodegener Dis Manag. 2020 Jun;10(3):113-118. doi: 10.2217/nmt-2020-0015. Epub 2020 Jun 5. Neurodegener Dis Manag. 2020. PMID: 32501735 Free article. No abstract available.

2

Therapeutic Targets for Multiple Sclerosis: Current Treatment Goals and Future Directions.

Smith AL, Cohen JA, Hua LH. Smith AL, et al. Among authors: hua lh. Neurotherapeutics. 2017 Oct;14(4):952-960. doi: 10.1007/s13311-017-0548-5. Neurotherapeutics. 2017. PMID: 28653282 Free PMC article. Review.

3

Multiple Sclerosis: Unprecedented Progress But Significant Challenges Ahead.

Conway DS, Hua LH, Cohen JA. Conway DS, et al. Among authors: hua lh. Neurotherapeutics. 2017 Oct;14(4):832-834. doi: 10.1007/s13311-017-0576-1. Neurotherapeutics. 2017. PMID: 28956322 Free PMC article. No abstract available.

4

Discontinuation of disease-modifying therapy in patients with multiple sclerosis over age 60.

Hua LH, Fan TH, Conway D, Thompson N, Kinzy TG. Hua LH, et al. Mult Scler. 2019 Apr;25(5):699-708. doi: 10.1177/1352458518765656. Epub 2018 Mar 20. Mult Scler. 2019. PMID: 29557704

5

Siponimod versus placebo in secondary progressive multiple sclerosis (EXPAND): a double-blind, randomised, phase 3 study.

Kappos L, Bar-Or A, Cree BAC, Fox RJ, Giovannoni G, Gold R, Vermersch P, Arnold DL, Arnould S, Scherz T, Wolf C, Wallström E, Dahlke F; EXPAND Clinical Investigators. Kappos L, et al. Lancet. 2018 Mar 31;391(10127):1263-1273. doi: 10.1016/S0140-6736(18)30475-6. Epub 2018 Mar 23. Lancet. 2018. PMID: 29576505 Clinical Trial.

6

Ten-year trends of palliative care utilization associated with multiple sclerosis patients in the United States from 2005 to 2014.

Lee YJ, Yoo JW, Hua L, Kim PC, Kim SJ, Shen JJ. Lee YJ, et al. J Clin Neurosci. 2018 Dec;58:13-19. doi: 10.1016/j.jocn.2018.10.082. Epub 2018 Oct 24. J Clin Neurosci. 2018. PMID: 30454687

7

Changes in patient-reported outcomes between continuers and discontinuers of disease modifying therapy in patients with multiple sclerosis over age 60.

Hua LH, Harris H, Conway D, Thompson NR. Hua LH, et al. Mult Scler Relat Disord. 2019 May;30:252-256. doi: 10.1016/j.msard.2019.02.028. Epub 2019 Mar 1. Mult Scler Relat Disord. 2019. PMID: 30851638

8

The Impact of Price Reductions After Loss of Exclusivity in a Cost-Effectiveness Analysis: Fingolimod Versus Interferon Beta-1a for the Treatment of Relapsing-Remitting Multiple Sclerosis.

Hua LH, Hersh CM, Morten P, Kusel J, Lin F, Cave J, Varga S, Herrera V, Ko JJ. Hua LH, et al. J Manag Care Spec Pharm. 2019 Apr;25(4):490-498. doi: 10.18553/jmcp.2019.25.4.490. J Manag Care Spec Pharm. 2019. PMID: 30917079 Free PMC article.

9

Duration of natalizumab therapy and reasons for discontinuation in a multiple sclerosis population.

Conway DS, Hersh CM, Harris HC, Hua LH. Conway DS, et al. Among authors: hua lh. Mult Scler J Exp Transl Clin. 2020 Jan 27;6(1):2055217320902488. doi: 10.1177/2055217320902488. eCollection 2020 Jan-Mar. Mult Scler J Exp Transl Clin. 2020. PMID: 32064117 Free PMC article.

10

Education Research: Multiple sclerosis and neuroimmunology fellowship training status in the United States.

Obeidat AZ, Jassam YN, Hua LH, Cutter G, Ford CC, Halper J, Lisak RP, Sicotte NL, Longbrake EE. Obeidat AZ, et al. Among authors: hua lh. Neurology. 2020 Mar 17;94(11):495-500. doi: 10.1212/WNL.0000000000009096. Epub 2020 Feb 27. Neurology. 2020. PMID: 32107321 Free PMC article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

46 results

Search Page

Filters